FOR IMMEDIATE RELEASE
SYKESVILLE, MD & BOSTON, MA – NeuImmune Inc. (“NeuImmune”), a biotechnology company pioneering precision glycoengineered biologics for orphan disease and enhanced immunologic delivery for specific disease conditions today announced a strategic collaboration with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”), a leader in cell programming and synthetic biology, to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to treat infection by filoviruses such as Ebola (EBOV) and Sudan Viruses (SUDV).
Collaboration Overview
Under the agreement, NeuImmune will leverage its proprietary geCHO BioDesign platform, which is capable of generating uniformly produced human-like glycoforms of therapeutic proteins and vaccine antigens. Ginkgo will apply its advanced cell-programming foundry, automation, and data/AI infrastructure to optimize production, scale manufacture, and support analytics of these glycoengineered biologics.
“Filoviral hemorrhagic fevers continue to be a serious global health risk, with 30–90% mortality, depending on the viral genus,” said Thomas Fuerst, Founder and Chairman of NeuImmune. “With our proprietary geCHO BioDesign platform and our deep expertise in precision engineering of biologics with distinct glycosylation signatures, we look forward to collaborating with Ginkgo to advance novel antibodies to treat these devastating viral infections. This strategic collaboration with Ginkgo will be foundational to leverage the strengths and platforms of our two companies to address this national security need.”
This project has been awarded through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a consortium overseen by the Biomedical Advanced Research and Development Authority (BARDA) and managed by Advanced Technology International (ATI), and funded in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); BARDA, under Other Transaction (OT) number #75A50123D00003.
About NeuImmune
NeuImmune Inc. is an early-stage biotechnology company founded by scientists from the University of Maryland, University of California, San Diego, and the Technical University of Denmark. It is focused on leveraging glycoengineering and targeted delivery (geCHO BioDesign and ICAM-1 targeting to enhance delivery across the blood-brain barrier) to address orphan diseases such as lysosomal storage disorders and infectious disease.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the timelines, outcomes and impact of the collaboration, the potential of the technologies and candidate therapeutics, regulatory pathways, and market opportunities. Such statements involve inherent risks and uncertainties, including the ability to achieve research milestones, successful scaling and manufacturing, regulatory approvals, and business development outcomes. Actual results may diger materially.
Media Contacts
NeuImmune, Inc.
Armand Girard
agirard@neuimmune.com